Abstract
There are only two three-piece inflatable penile prostheses (IPP) available to patients in the American market: the AMS (American Medical Systems) 700TM series (Boston Scientific, Massachusetts) and the Coloplast Titan® series (Coloplast, Minnesota), and data comparing the two are scant. The aim of our study was to summarize the current scientific evidence comparing the two.A systematic literature review was conducted on PubMed. A 10-year filter was placed to include only studies published after Coloplast launched the Titan Touch® release pump. Eligibility criteria included articles discussing specifically the AMS 700TM and Coloplast Titan® models. Further searches for studies on patient/partner satisfaction were conducted. s were reviewed to include studies focusing specifically on the models we are studying and studies on patient satisfaction using the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire.The Coloplast device demonstrated slightly greater resistance to the stimulated forces of penetration and gravity. Coloplast implants coated with vancomycin/gentamicin had the highest infection rate followed by the AMS penile prosthesis and the rifampin/gentamicin coating had the lowest infection rate. Prosthesis durability and survival were similar between both brands. Overall satisfaction was high but comparisons are inconsistent.The literature is inconclusive about which device is superior. We suggest randomized, multicenter, prospective studies to help further elucidate the highlights of each product.
Highlights
BackgroundErectile dysfunction (ED) is a recurrent or consistent inability to acquire or sustain an erection of sufficient rigidity and duration for sexual intercourse [1]
Of the men in the study, 58% had actively sought medical attention for ED and only 16% were currently being treated with oral phosphodiesterase-5 inhibitor (PDE-5) therapy [3]
Given the difference in device design, we aimed to review the current scientific literature comparing these two inflatable penile prostheses (IPP), which includes a biomechanical comparison, infection rates, the use of IPPs in Peyronie’s disease (PD), and patient and partner satisfaction
Summary
Erectile dysfunction (ED) is a recurrent or consistent inability to acquire or sustain an erection of sufficient rigidity and duration for sexual intercourse [1]. ED has been estimated to affect approximately 5%-20% of men. Differences in the definitions of ED, as well as methodological differences, may explain the variety in reported prevalence rates [2]. The Multinational Men’s Attitudes to Life Events and Sexuality study identified the overall prevalence of ED to be 16% and found the prevalence to be 20% in the United States. The prevalence increased with age and other comorbid medical conditions such as cardiovascular disease, hypertension, dyslipidemia, and depression. Of the men in the study, 58% had actively sought medical attention for ED and only 16% were currently being treated with oral phosphodiesterase-5 inhibitor (PDE-5) therapy [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
